ES2124263T3 - Peptidos con una actividad de liberacion de hormonas de crecimiento. - Google Patents

Peptidos con una actividad de liberacion de hormonas de crecimiento.

Info

Publication number
ES2124263T3
ES2124263T3 ES92919262T ES92919262T ES2124263T3 ES 2124263 T3 ES2124263 T3 ES 2124263T3 ES 92919262 T ES92919262 T ES 92919262T ES 92919262 T ES92919262 T ES 92919262T ES 2124263 T3 ES2124263 T3 ES 2124263T3
Authority
ES
Spain
Prior art keywords
peptidos
growth hormone
hormone release
release activity
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92919262T
Other languages
English (en)
Inventor
Cyril Y Bowers
David Coy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of ES2124263T3 publication Critical patent/ES2124263T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBEN NUEVOS PEPTIDOS DE LA FORMULA A1 C2 CIMIENTO CUANDO SE ADMINISTRAN A LOS ANIMALES. ESTOS PEPTIDOS SE PUEDEN EMPLEAR TERAPEUTICAMENTE.
ES92919262T 1991-08-22 1992-08-20 Peptidos con una actividad de liberacion de hormonas de crecimiento. Expired - Lifetime ES2124263T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/748,350 US5663146A (en) 1991-08-22 1991-08-22 Polypeptide analogues having growth hormone releasing activity

Publications (1)

Publication Number Publication Date
ES2124263T3 true ES2124263T3 (es) 1999-02-01

Family

ID=25009088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92919262T Expired - Lifetime ES2124263T3 (es) 1991-08-22 1992-08-20 Peptidos con una actividad de liberacion de hormonas de crecimiento.

Country Status (26)

Country Link
US (2) US5663146A (es)
EP (1) EP0605484B1 (es)
JP (1) JP3179489B2 (es)
KR (1) KR100247212B1 (es)
CN (1) CN1035256C (es)
AT (1) ATE172742T1 (es)
AU (1) AU666673B2 (es)
BG (1) BG62655B1 (es)
BR (2) BR9206398A (es)
CA (1) CA2116120C (es)
CZ (1) CZ293281B6 (es)
DE (1) DE69227462T2 (es)
DK (1) DK0605484T3 (es)
ES (1) ES2124263T3 (es)
FI (2) FI120095B (es)
HU (1) HU223664B1 (es)
IL (1) IL102848A (es)
MX (1) MX9204861A (es)
NO (1) NO314695B1 (es)
NZ (1) NZ244034A (es)
PL (1) PL169562B1 (es)
RO (1) RO112507B1 (es)
RU (1) RU2126014C1 (es)
SK (1) SK282895B6 (es)
WO (1) WO1993004081A1 (es)
ZA (1) ZA926337B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
WO1995017423A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU683121B2 (en) * 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
AU711104B2 (en) * 1995-06-22 1999-10-07 Novo Nordisk A/S Compounds with growth hormone releasing properties
KR20000010626A (ko) * 1996-04-24 2000-02-25 한센 핀 베네드, 안네 제헤르 성장호르몬 방출성을 갖는 화합물
EP1005484A1 (en) 1997-06-20 2000-06-07 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
HUP0100777A3 (en) 1998-01-16 2001-12-28 Novo Nordisk As Tripeptides with growth hormone releasing properties, pharmaceutical compositions comprising thereof and their use
WO1999039730A1 (en) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Oral preparations containing peptides promoting the secretion of growth hormone
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
JP2002525265A (ja) * 1998-08-14 2002-08-13 アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド 成長ホルモン放出活性を有する化合物
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
JP2002542151A (ja) * 1999-02-18 2002-12-10 科研製薬株式会社 成長ホルモン分泌促進物質としての新規なアミド誘導体
US7022677B1 (en) 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
CN1367792A (zh) * 1999-06-25 2002-09-04 研究及应用科学协会股份有限公司 促生长素抑制素激动剂
ES2401939T3 (es) * 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
JP4691298B2 (ja) * 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AR037038A1 (es) 2001-10-26 2004-10-20 Baylor College Medicine Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
AU2002357143B2 (en) 2001-12-11 2009-07-30 Advisys, Inc. Growth hormone releasing hormone supplementation for treating chronically ill subjects
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
US7250405B2 (en) * 2002-02-07 2007-07-31 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
US7396846B2 (en) * 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2004017986A1 (en) 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CA2513743C (en) * 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CA2575926C (en) * 2003-08-04 2014-02-25 Advisys, Inc. Canine specific growth hormone releasing hormone
US7399826B1 (en) 2003-10-02 2008-07-15 Ali Sadat M Peptide for promoting healing of fractures
ATE467417T1 (de) * 2003-12-31 2010-05-15 VGX Pharmaceuticals LLC Reduzierung von arthritis und lahmheit bei personen unter supllement von wachstumshormon freisetzendem hormon (ghrh)
WO2005073371A2 (en) * 2004-01-20 2005-08-11 Advisys, Inc. Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20060025368A1 (en) * 2004-07-23 2006-02-02 Advisys, Inc. Growth hormone releasing hormone enhances vaccination response
WO2006023608A2 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
JP2009506119A (ja) 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
PL2069352T3 (pl) 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
MA56396A (fr) 2019-06-27 2022-05-04 Cytokinetics Inc Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
JPS58501861A (ja) * 1981-12-28 1983-11-04 ベツクマン・インストルメンツ・インコ−ポレ−テツド 下垂体成長ホルモン放出活性を有する合成ペプチド
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB8314646D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Pharmaceutical amides
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
AU637316B2 (en) * 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU628322B2 (en) * 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68912775T2 (de) * 1988-05-11 1994-06-30 Polygen Holding Corp Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
WO1992001709A1 (en) 1990-07-24 1992-02-06 Eastman Kodak Company Process for synthesizing peptides
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2116120A1 (en) 1993-02-23
CN1073684A (zh) 1993-06-30
DE69227462T2 (de) 1999-04-08
NZ244034A (en) 1995-08-28
IL102848A (en) 1998-04-05
CA2116120C (en) 2002-12-03
KR100247212B1 (ko) 2000-03-15
NO940592D0 (no) 1994-02-21
NO314695B1 (no) 2003-05-05
DE69227462D1 (de) 1998-12-03
ZA926337B (en) 1993-04-22
HU223664B1 (hu) 2004-11-29
CZ40094A3 (en) 1994-11-16
PL169562B1 (pl) 1996-08-30
AU2541692A (en) 1993-03-16
IL102848A0 (en) 1993-01-31
SK20494A3 (en) 1994-10-05
FI120691B (fi) 2010-01-29
BR1100309A (pt) 2000-08-01
US5776901A (en) 1998-07-07
NO940592L (no) 1994-04-14
AU666673B2 (en) 1996-02-22
WO1993004081A1 (en) 1993-03-04
HU9400495D0 (en) 1994-05-30
HUT69178A (en) 1995-08-28
BG62655B1 (bg) 2000-04-28
EP0605484B1 (en) 1998-10-28
BR9206398A (pt) 1994-12-27
DK0605484T3 (da) 1999-07-05
SK282895B6 (sk) 2003-01-09
JP3179489B2 (ja) 2001-06-25
CZ293281B6 (cs) 2004-03-17
RO112507B1 (ro) 1997-10-30
ATE172742T1 (de) 1998-11-15
US5663146A (en) 1997-09-02
EP0605484A1 (en) 1994-07-13
CN1035256C (zh) 1997-06-25
FI940807L (fi) 1994-02-21
JPH07507039A (ja) 1995-08-03
BG98489A (bg) 1995-02-28
RU2126014C1 (ru) 1999-02-10
FI120095B (fi) 2009-06-30
FI940807A0 (fi) 1994-02-21
MX9204861A (es) 1994-06-30
FI20050467L (fi) 2005-05-02

Similar Documents

Publication Publication Date Title
ES2124263T3 (es) Peptidos con una actividad de liberacion de hormonas de crecimiento.
GR890100838A (el) Νέα ?εραπευτικώς δραστική ένωσις και μέ?οδος για την παραγωγή της.
IT1217346B (it) Prodotto comprendente un composto organico del silicato combinato con una sostanza cosmeticamente attiva
NO165237C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzensulfonamido-indanylforbindelser.
ES2067244T3 (es) Compuestos peptidicos que presentan una actividad de liberacion de la hormona del crecimiento.
IT8820550A0 (it) Benzammidi sostituite farmacologicamente attive.
ES8602816A1 (es) Un procedimiento para la preparacion de nuevos antibioticos de cefalosporina.
SE8205135D0 (sv) Benzamido-derivatives
IT1227459B (it) Dispositivo per fissare una lenza alla punta di una canna da pesca.
ATE118007T1 (de) Penemderivate.
DK576687A (da) Terapeutisk aktive alkensyrederivater
DK472189A (da) Vaeksthormon
IT7953150V0 (it) Fermaglio per paletti specialmente per la coltiva ione della vite
ES8102554A1 (es) Un procedimiento para la preparacion de 1-metil-2-(3-sulfa- mil-4'-clorobenzamido)-isoinodlina
IT8553017U1 (it) Perfezionamento alla macchina srotolatrice di balle di foraggio cilindriche.
IT1233861B (it) Composizione di composti che migliorano l'attivita' analgesica, antipiretica e antiinfiammatoria
ES2098666T3 (es) Derivados de monensina.
GB1167407A (en) Novel Reserpine Derivative having Pharmacological Activity and Compositions containing the said Derivative
IT7823549A0 (it) Composto di pentapeptide adattivita' analgesica.
IT8701237A0 (it) Procedimento per la colata con calcestruzzo del dorso di una trave di copertura a v aperta
IT1222097B (it) Perfezionamenti ad una siringa dentale
FI915516A7 (fi) Menetelmä farmaseuttisesti aktiivisten 2-(pyridyylialkeenisulfinyyli)bentsimidatsolien valmistamiseksi
IT1150828B (it) Suola portante per calzature, particolarmente per calzature femminili e procedimento per ottenere una calzatura con l'impiego di tale suola
GT199000001A (es) Acidos oxapenem -3- carboxilicos y su utilizacion como inhi-bidores de beta- lactamasas.
SU1075674A1 (ru) 2,3,2,3-Тетрагидро-3,3-тетрацианметилен-5,5-бис-as-триазин, обладающий противовоспалительной и анальгетической активностью

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 605484

Country of ref document: ES